Akanda

Akanda Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Akanda (AKAN) as of Oct 26, 2026 is 14.74 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 97.18 % — a change of -84.83% (lower).

Cash Conversion

14.74 %

YoY

-84.83%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Akanda is 2025 14.74 % . Cash Conversion Rate (OCF/Net Income) of Akanda was 2024 97.18 % . It decreases by -84.83% lower compared to the previous year.

The Akanda Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
34.01 USD
Jan 1, 2020
58.79 USD
Jan 1, 2021
80.64 USD
Jan 1, 2022
98.38 USD
Jan 1, 2023
4.65 USD
Jan 1, 2024
97.18 USD
Jan 1, 2025
14.74 USD
The Akanda Cash Conversion history
YEARCash ConversionYoY
14.74 %-84.83%
97.18 %+1,990.11%
4.65 %-95.27%
98.38 %+22.00%
80.64 %+37.17%
58.79 %+72.84%
34.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Cash Conversion Rate (OCF/Net Income) of Akanda is 14.74 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Akanda changed from 97.18 % to 14.74 %, representing a -84.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Akanda since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Akanda with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Akanda

All Key Metrics — Akanda